SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
明亮听芹
Lv1
90 积分
2024-01-01 加入
最近求助
最近应助
互助留言
Causal relationship between lung diseases and risk of esophageal cancer: insights from Mendelian randomization
11天前
已完结
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
1个月前
已完结
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
2个月前
已完结
P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial
2个月前
已关闭
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer
2个月前
已关闭
1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
3个月前
已完结
没有进行任何应助
感谢
2个月前
啊,这只有摘要吗
3个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论